We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Minirin Melt in Patients With Nocturia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01222598
First Posted: October 18, 2010
Last Update Posted: October 8, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ferring Pharmaceuticals
October 5, 2010
October 18, 2010
October 8, 2012
September 2008
December 2010   (Final data collection date for primary outcome measure)
Number of participants with adverse events [ Time Frame: 12 months ]
Same as current
Complete list of historical versions of study NCT01222598 on ClinicalTrials.gov Archive Site
  • Number of participants with nocturnal voiding [ Time Frame: 12 months ]
  • Number of participants with adverse events [ Time Frame: 12 months ]
Same as current
Not Provided
Not Provided
 
A Study of Minirin Melt in Patients With Nocturia
Minirin Melt Tolerance With Nocturia in the Common Practice Conditions in Czech Republic
This is a confirmation of safety profile for Minirin Melt in clinical practice.
Not Provided
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Primary care clinic
Nocturia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
588
March 2011
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients suffering from Nocturia

Exclusion Criteria:

  • habitual or psychogenic polydipsia
  • known or suspected cardiac insufficiency and other conditions requiring treatment with diuretics
  • moderate and severe renal insufficiency
  • know hyponatremia
  • syndrome of inappropriate ADH secretion
Sexes Eligible for Study: All
18 Years to 64 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Czech Republic
 
 
NCT01222598
FE992026 CS38
No
Not Provided
Not Provided
Ferring Pharmaceuticals
Ferring Pharmaceuticals
Not Provided
Study Director: Clinical Development Support Ferring Pharmaceuticals
Ferring Pharmaceuticals
October 2012